07 February 2024
07 February 2024
The acquisition, which also includes Phase II asset AL101, closes gap to SpringWorks’ FDA-approved Ogsiveo.
Vertex says that Phase III data shows that the new vanza triple is superior to Trikafta in controlling sweat chloride levels.
In the trial, VVD-130850 will be analysed as a monotherapy and along with immune checkpoint inhibitors.
The alliance aims to create an eDiary library in eCOA that is tailored to Sanofi's vaccines.
This multicentre, double-masked, randomised, parallel group trial is set to recruit 150 DME patients.
The company received clearance to commence the trial from from the US Food and Drug Administration (FDA) and Australia's Therapeutic Goods Administration (TGA).
The BariTon implant is designed to mimic the results of sleeve gastrectomy and bypass surgery.
RT-111 could offer an alternative dosing regimen for patients with psoriasis and other conditions compared to injectable biologics.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
